FDA rejects expanded use of Vertex's cystic fibrosis drug

(Reuters) - The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc's bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday.